Show simple item record

dc.contributor.authorStrauss, Michél
dc.contributor.authorSmith, Wayne
dc.contributor.authorSchutte, Aletta E.
dc.contributor.authorFedorova, Olga V.
dc.identifier.citationStrauss, M. et al. 2019. The Na+K+-ATPase inhibitor marinobufagenin and early cardiovascular risk in humans: a review of recent evidence. Current hypertension reports, 21(5): Article no 38. []en_US
dc.identifier.issn1534-3111 (Online)
dc.description.abstractPurpose of Review This review synthesizes recent findings in humans pertaining to the relationships between marinobufagenin (MBG), a steroidal Na+/K+-ATPase inhibitor and salt-sensitivity biomarker, and early cardiovascular risk markers. Recent Findings Twenty-four-hour urinary MBG strongly associates with habitual salt intake in young healthy adults (aged 20–30 years). Furthermore, in young healthy adults free of detected cardiovascular disease, MBG associates with increased large artery stiffness and left ventricular mass independent of blood pressure. These findings in human studies corroborate mechanistic data from rat studies whereby stimulation of MBG by a high salt intake or MBG infusion increased vascular fibrosis and cardiac hypertrophy. Summary Twenty-four-hour urinary MBG may be a potential biomarker of early cardiovascular risk. Adverse associations between MBG—which increases with salt consumption—and early cardiovascular risk markers support the global efforts to reduce population-wide salt intake in an effort to prevent and control the burden of non-communicable diseasesen_US
dc.subjectEarly cardiovascular risken_US
dc.titleThe Na+K+-ATPase inhibitor marinobufagenin and early cardiovascular risk in humans: a review of recent evidenceen_US
dc.contributor.researchID22945717 - Smith, Wayne
dc.contributor.researchID10922180 - Schutte, Aletta Elisabeth
dc.contributor.researchID23423714 - Strauss, Michél

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record